Novartis has backup for false protection against Voltaren counterfeits
This article was originally published in Scrip
Executive Summary
Supplies of Novartis' Voltaren (diclofenac sodium) are safe despite reports that the company may have purchased anti-counterfeiting technology that is not as secure as promised for the injectable form of its non-steroidal anti-inflammatory drug (NSAID).